Metabolic · Generation 2

TirzeLeanTirzepatide

Dual GLP-1 + GIP agonist · weight, glucose, sleep apnea and heart · the molecule in Mounjaro and Zepbound

The ReferenceBenefits, protocols and preparationOpen the reference →
Purity
≥99%
Format
10mg · 20mg
COA
Verifiable in the kit
Receptors
GLP-1+GIP
Molecule approved in United States, European Union, United Kingdom and 5 more · 2022What this means ›
🇺🇸 United States · Approved🇪🇺 European Union · Approved🇬🇧 United Kingdom · Approved🇯🇵 Japan · Approved🇨🇳 China · Approved🇨🇦 Canada · Approved🇦🇺 Australia · Approved🇧🇷 Brazil · Approved

The molecule is approved as a medicine in United States, European Union, United Kingdom and 5 more, under the brand Mounjaro · Zepbound. In the US it holds five indications: Mounjaro for type 2 diabetes in adults (May 2022) and from age 10 (SURPASS-PEDS, 19 December 2025), Zepbound for weight management (November 2023), Zepbound for obstructive sleep apnoea (December 2024) and Mounjaro to reduce cardiovascular risk in type 2 diabetes (August 2026, SURPASS-CVOT). The European Union, the UK, Japan, China, Canada, Australia and Brazil have approved it for type 2 diabetes and, in most, for weight management; in Europe the EMA added the heart-failure data to the label (January 2026) without a separate indication. It is the dual GLP-1 + GIP agonist with the most human data on the market.

What is approved is the molecule under that pharmaceutical brand. Our vial is research material (RUO).

Source: FDA · Mounjaro (2022; desde 10 años, 19 dic 2025; riesgo cardiovascular ago 2026), Zepbound (2023; apnea del sueño dic 2024) · EMA (IC en ficha, ene 2026), MHRA, MHLW, NMPA, Health Canada, TGA y Anvisa

For research use only (RUO) Ships from Quito · EC 1-3 days · LATAM 4-10 Arrives damaged? We replace it free COA per batch
CAS · 2023788-19-2 MW · 4813.45 Da Stock · Available
How it works

4 mechanisms. One peptide.

What this peptide does at the cellular level, in plain words.

GLP-1 activation

Receptor agonist with greater potency than semaglutide in some models.

GIP activation

Dual agonism: also activates GIP receptor. Synergizes metabolic action.

Enhanced satiety

Dual mechanism amplifies appetite suppression vs mono-agonists.

Recomposition

Reports of up to 22.5% body weight loss in phase III studies.

Why combine it

Lose weight & curb appetite

See all combinations in the Consultation →
The compound

Technical description.

Tirzepatide is a synthetic dual agonist peptide targeting both GLP-1 and GIP receptors simultaneously, distinguishing it from single-receptor metabolic peptides like semaglutide. As the active molecule in Mounjaro and Zepbound, tirzepatide has been characterized in over 100 clinical and preclinical studies for its effects on glycemic control, body composition, and energy expenditure.

SuperBio Labs Tirzepatide is supplied as lyophilized powder with ≥99% HPLC-verified purity. Each lot ships with a third-party Certificate of Analysis confirming peptide identity by LC-MS, peptide content, and endotoxin levels.

The dual receptor mechanism is what makes tirzepatide a reference compound in metabolic research: GLP-1 activation modulates appetite and glucose-dependent insulin secretion, while GIP activation improves insulin sensitivity and fat metabolism. Beyond weight, its human trials have already shown: sleep apnea (the molecule in Zepbound, December 2024), heart (the molecule in Mounjaro lowers cardiovascular risk in type 2 diabetes since August 2026; SURPASS-CVOT, NEJM 2025: as protective as dulaglutide with 16% fewer deaths from any cause), heart failure with obesity (SUMMIT: 38% fewer hospitalizations or cardiovascular deaths; no indication yet), kidney (21% fewer kidney events than dulaglutide), fatty liver with inflammation (phase 2) and psoriasis with excess weight (phase 3b with ixekizumab, 2026). For type 2 diabetes it is approved from age 10.

Informed professional research use only.

Your complete kit, ready to apply.

We don't just hand you the vial. Every Tirzepatide purchase includes everything you need to apply it safely, with a clear protocol and our team available 24/7.

Tirzepatide vial

Lyophilized · HPLC purity ≥99% · Batch with COA

BAC

Bacteriostatic water 30ml

Sterile diluent · 0.9% benzyl alcohol

3ml

1 extraction syringe 3ml

21G needle · For peptide reconstitution

5–10 insulin syringes (29G)

10mg → 5 · 20mg → 10 · 1×/week

70%

6–11 alcohol wipes 70%

10mg → 6 · 20mg → 11 · 1 per application + 1 to reconstitute

Your protocol and product sheet, in the app

Free app · Week-by-week protocol, product sheet and usage guide

Visual step-by-step guide

8 steps · From opening the kit to application

SuperBio OS · Support

App · Tracking · Human team 24/7

About supplies: the quantity of syringes and wipes adjusts automatically based on the presentation you choose. For extended cycles (BPC-157, GHK-Cu and similar) we cap supplies at 30 days — beyond that, 29G insulin syringes and 70% alcohol wipes are pharmacy items available without prescription in any city.

Before you buy · from any store

How to choose where to buy peptides.

01
Per-batch, verifiable COA The certificate exists and can be checked — not "available on request".
→
02
HPLC purity + LC-MS identity How much is in the vial, and that it is the right peptide.
→
03
Endotoxins tested LAL test within range — not just purity.
→
04
2-8°C cold chain Documented end to end, not promised.
→
05
Traceability and support Lot number on the vial and someone who answers after.

This product meets all five — your batch COA ships with the kit.

Recommended application protocol.

The official protocol included in the kit. If you have pre-existing medical conditions, consult a professional before starting.

Reconstitution
1 ml (10 mg) · 2 ml (20 mg) of bacteriostatic water → 10 mg/ml
Starting dose
1.5 mg
Target dose
1.5 → 3 mg
Frequency
1×/week
Cycle duration
16 weeks
Application site
Subcutaneous · abdomen / thigh / arm
Storage (reconstituted)
60 days refrigerated (2–8°C)

Recommended titration

Wk 1–4: 1.5 mg → Wk 5–8: 2 mg → Wk 9–12: 2.5 mg → Wk 13–16: 3 mg

Note

Dual GLP-1 + GIP agonist. Same day each week.

When to use Tirzepatide.

Weight, best backed

The dual incretin with the most human data on the market.

High glucose

Insulin resistance · superior to semaglutide in SURPASS-2.

Sleep apnea

Moderate-to-severe apnea with obesity · the molecule in Zepbound, Dec 2024 (SURMOUNT-OSA).

Fatty liver

Fatty liver with inflammation: resolved it without worsening fibrosis (phase 2).

First incretin

A more tolerable entry point than retatrutide.

Triglycerides

About −25% in trials.

Heart

Diabetes with cardiovascular risk: the molecule in Mounjaro lowers it (Aug 2026); 16% fewer deaths than dulaglutide (SURPASS-CVOT).

Heart failure

With preserved ejection fraction and obesity: 38% fewer hospitalizations or deaths (SUMMIT, phase 3; no indication yet).

Psoriasis with excess weight

With ixekizumab, clear skin plus −10% weight in 27% vs 6% (phase 3b, 2026).

Honest side effects.

The classic GLP-1 profile, very well documented. In SURMOUNT-1 (5–15 mg): nausea 25–33%, diarrhea 19–23%, constipation 12–17%, vomiting 8–12% (placebo 2–10%). Mostly mild or moderate and concentrated during dose escalation.

Discontinuation due to adverse events was 4–7% (placebo 3%). Others: reflux, fatigue the day after dosing, and muscle loss without enough protein and strength training. Two class notices: if you are having surgery or an endoscopy under sedation, say you use a GLP-1 (slow gastric emptying; FDA label, Nov 2024); and seek care at once for sudden vision loss (NAION, "very rare" with semaglutide per the EMA, Jun 2025; no signal for tirzepatide). If you vomit or have diarrhea, hydrate: dehydration can harm the kidney. Do not use with prior pancreatitis, medullary thyroid cancer or MEN2, pregnancy, or together with another GLP-1.

Technical specifications

CAS number2023788-19-2
Molecular weight4813.45 Da
Purity (HPLC)≥99%
FormatLyophilized powder
Quantity10 / 20 mg per vial
Endotoxins<1.0 EU/mg
Storage−20 °C, protected from light
UseUse under professional judgment

Also in Metabolic Series